scholarly journals Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous Prostate Cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree

2018 ◽  
Vol 38 (8) ◽  
pp. 4847-4852 ◽  
Author(s):  
WEIDONG LIU ◽  
DONGWEI ZHANG ◽  
SANDA A. TAN ◽  
XIULI LIU ◽  
JINPING LAI
Keyword(s):  
Prostate Cancer ◽  
Sigmoid Colon ◽  
Colon Adenocarcinoma ◽  
Family Pedigree ◽  
The Family

scholarly journals Filiform polyposis with sigmoid colon adenocarcinoma: a case report

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Takayuki Okuno ◽  
Takamitsu Kanazawa ◽  
Hirohisa Kishi ◽  
Hiroyuki Anzai ◽  
Koji Yasuda ◽  
...  
Keyword(s):  
Sigmoid Colon ◽  
Colon Adenocarcinoma ◽  
Resected Specimen ◽  
Normal Colonic Mucosa ◽  
Histological Findings ◽  
P53 Expression ◽  
History Of ◽  
Reparative Process ◽  
Inflammatory Polyposis ◽  
Filiform Polyposis

Abstract Background Filiform polyposis is a rare form of inflammatory polyposis, which is occasionally formed in the colon of patients with history of inflammatory bowel disease (IBD). It is characterized by presence of several to hundreds of slender, worm-like polyps in the colon lined by histologically normal colonic mucosa and often coalesce, resulting in a tumor-like mass. Filiform polyposis is most frequently associated with a post-inflammatory reparative process in patients with IBD history, and only cases of filiform polyposis occurring in patients without IBD history have been reported. Filiform polyposis has been considered as a benign inflammatory polyposis without any risk of dysplasia, while the possibility of carcinogenesis of inflammatory polyps is not fully excluded. To date, only three cases of filiform polyposis coexisting with dysplasia have been reported. Case presentation A 59-year-old male patient with no past medical history of IBD underwent laparoscopic sigmoidectomy for obstructive filiform polyposis, which was associated with sigmoid colon adenocarcinoma. Based on the histological findings of the resected specimen, invasive sigmoid colon adenocarcinoma was surrounded by filiform polyposis, and adenocarcinoma also scattered uniformly on the surface of filiform polyposis. In immunohistochemistry, abnormal p53 expression was observed in adenocarcinoma, while it was not shown in mucosa on filiform polyposis. Conclusions This is the fourth case of filiform polyposis that is closely associated with colon dysplasia or adenocarcinoma based on histological findings. However, immunohistochemical findings did not support the theory that inflammation initiates adenocarcinoma in filiform polyposis like IBD. Hence, further immunohistochemical and genetic analyses are needed to clarify the association between filiform polyposis and carcinogenesis.

scholarly journals Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic

2014 ◽  
Vol 8 (11-12) ◽  
pp. 783 ◽  
Author(s):  
Richard Walker ◽  
Alyssa Louis ◽  
Alejandro Berlin ◽  
Sheri Horsburgh ◽  
Robert G. Bristow ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
High Risk ◽  
Prostate Cancer Screening ◽  
Brca2 Mutation ◽  
Aggressive Disease ◽  
Mutation Carriers ◽  
The Family ◽  
History Of ◽  
Prevention Clinic

Introduction: The prostate-specific antigen (PSA) era and resultant early detection of prostate cancer has presented clinicians with the challenge of distinguishing indolent from aggressive tumours. Mutations in the BRCA1/2 genes have been associated with prostate cancer risk and prognosis. We describe the prostate cancer screening characteristics of BRCA1/2 mutation carriers, who may be classified as genetically-defined high risk, as compared to another high-risk cohort of men with a family history of prostate cancer to evaluate the utility of a targeted screening approach for these men.Methods: We reviewed patient demographics, clinical screening characteristics, pathological features, and treatment outcomes between a group of BRCA1 or BRCA2 mutation carriers and age-matched men with a family history of prostate cancer followed at our institutional Prostate Cancer Prevention Clinic from 1995 to 2012.Results: Screening characteristics were similar between the mutation carriers (n = 53) and the family history group (n = 53). Some cancers would be missed in both groups by using a PSA cut-off of >4 ug/L. While cancer detection was higher in the family history group (21% vs. 15%), the mutation carrier group was more likely to have intermediate- or high-risk disease (88% vs. 36%). BRCA2 mutation carriers were more likely to have aggressive disease, biological recurrence, and distant metastasis.Conclusions: In our cohort, regular screening appears justified for detecting prostate cancer in BRCA1 and BRCA2 carriers and other high-risk populations. Lowering PSA cut-offs and defining monitoring of PSA velocity as part of the screening protocol may be useful. BRCA2 is associated with more aggressive disease, while the outcome for BRCA1 mutation carriers requires further study. Large multinational studies will be important to define screening techniques for this unique high-risk population.

Familial prostate cancer from the Family-Cancer Database

2000 ◽  
Vol 36 (2) ◽  
pp. 229-234 ◽  
Author(s):  
K. Hemminki ◽  
C. Dong
Keyword(s):  
Prostate Cancer ◽  
The Family

Metachronous prostate and colon adenocarcinomas

2021 ◽  
Vol 14 (5) ◽  
pp. e242273
Author(s):  
Rawan A Rahman AlHarmi ◽  
Abdulhakim Motea Hezam ◽  
Jalila Sayed Adnan ◽  
Yaser Alderazi
Keyword(s):  
Prostate Cancer ◽  
Adjuvant Chemotherapy ◽  
Hormonal Therapy ◽  
Primary Tumour ◽  
Colon Adenocarcinoma ◽  
Prostate Adenocarcinoma ◽  
Therapy Management ◽  
Multiple Factors ◽  
Multiple Primaries ◽  
To Receive

Multiple primaries in patients with prostate cancer are uncommon. We report a case of prostate adenocarcinoma who did not receive any form of treatment, diagnosed 7 months later with colon adenocarcinoma. The patient underwent right extended hemicolectomy and recovered well. He is planned to receive adjuvant chemotherapy and hormonal therapy. Management of such cases can present a dilemma and multiple factors must be taken into consideration, particularly when the first primary tumour is still active.

Genetics: The Family Pedigree

2012 ◽  
Author(s):  
Julia Eggert ◽  
Heide S. Temples
Keyword(s):  
Family Pedigree ◽  
The Family

scholarly journals Urachal Mucinous Cystic Tumor of Low Malignant Potential with Concurrent Sigmoid Colon Adenocarcinoma

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Kelly Brennan ◽  
Paul Johnson ◽  
Heather Curtis ◽  
Thomas Arnason
Keyword(s):  
Sigmoid Colon ◽  
Incidental Finding ◽  
Colon Adenocarcinoma ◽  
Malignant Potential ◽  
Cystic Tumor ◽  
Mucinous Cystic Tumor ◽  
Therapeutic Implications ◽  
Diagnostic Pitfall ◽  
Low Malignant Potential ◽  
Peritoneal Spread

Urachal mucinous tumors are rare neoplasms with behaviour that can range from relatively benign to malignancy that can spread distantly or throughout the peritoneum as pseudomyxoma peritonei or peritoneal carcinomatosis. Here we describe a unique case of urachal mucinous cystic tumor of low malignant potential confined to an intact cyst at the dome of the urinary bladder, without rupture or peritoneal spread. The urachal mucinous tumor was an incidental finding on a staging CT scan performed for sigmoid colon adenocarcinoma. We believe that this case illustrates a potential diagnostic pitfall which could have prognostic and therapeutic implications. Due to the intestinal phenotype of these neoplasms, a urachal tumor of low malignant potential could be mistaken for metastatic spread from a colonic adenocarcinoma in the rare situation such as this case, where the two neoplasms occur concurrently.

A Rare Case of Metastases to the Maxillary Sinus from Sigmoid Colon Adenocarcinoma

ORL ◽  
2002 ◽  
Vol 64 (5) ◽  
pp. 364-367 ◽  
Author(s):  
Elona Cama ◽  
Stefania Agostino ◽  
Riccardo Ricci ◽  
Emanuele Scarano
Keyword(s):  
Maxillary Sinus ◽  
Sigmoid Colon ◽  
Rare Case ◽  
Colon Adenocarcinoma

The use of panitumumab in the treatment of chemoresistant metastatic sigmoid colon adenocarcinoma: a clinical case

Pharmateca ◽  
2020 ◽  
Vol 11_2020 ◽  
pp. 68-72
Author(s):  
S.A. Protsenko Protsenko ◽  
G.M. Teletaeva Teletaeva ◽  
E.A. Degtyareva Degtyareva ◽  
A.I. Semenova Semenova ◽  
D.Kh. Latipova Latipova ◽  
...  
Keyword(s):  
Sigmoid Colon ◽  
Clinical Case ◽  
Colon Adenocarcinoma

Multiple Tumor Marker Elevation in Androgen Ablation-Refractory Prostate Cancer with Long-Term Response to Metronomic Chemotherapy: A Case Report

2010 ◽  
Vol 25 (4) ◽  
pp. 243-247 ◽  
Author(s):  
Mariangela Massaccesi ◽  
Franca Forni ◽  
Pasquale Spagnuolo ◽  
Gabriella Macchia ◽  
Samantha Mignogna ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Colon Adenocarcinoma ◽  
Metronomic Chemotherapy ◽  
Serum Levels ◽  
Hormone Refractory Prostate Cancer ◽  
Multiple Tumor ◽  
Androgen Ablation ◽  
Antiangiogenic Therapies ◽  
Specific Tumor ◽  
Hormone Refractory

Outcomes in hormone-refractory prostate cancer are very poor. The time from progression to death is only 12–19 months. We present the case of a 69-year-old man with hormone-refractory prostate cancer and bone metastases treated with metronomic chemotherapy (cyclophosphamide based). He had had a colon adenocarcinoma ten years before. The atypical features of this case were an unusually long-lasting response to metronomic chemotherapy and an increase in serum levels of some non-prostate-specific tumor markers (CEA and CA 19–9) that was not related to a relapse of colon cancer. We hypothesize a potential role of hypoxia inducing CA 19–9 and CEA expression in tumor cells, which may predict the development of progressive resistance to antiangiogenic therapies.

Sign in / Sign up

Export Citation Format

Share Document